Printer friendly
Acronymfinder

What does GC stand for?

GC stands for Gemcitabine/Carboplatin


This definition appears very rarely and is found in the following Acronym Finder categories:

  • Science, medicine, engineering, etc.

See other meanings of GC

Other Resources:
We have 91 other definitions for GC in our Acronym Attic

Samples in periodicals archive:

Final efficacy and safety results of a randomized phase II study of the PARP inhibitor iniparib (BSI201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple negative breast cancer (TNBC) [3] Iniparib is a novel small molecule that inhibits PARP1, a nuclear enzyme that promotes DNA repair through the base-excision repair pathway.
Clinical data and interviewed thought leaders indicate that nanoparticle paclitaxel in combination with carboplatin, ipilimumab (Bristol-Myers Squibb's Yervoy) in combination with paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin, and necitumumab (ImClone Systems/Bristol-Myers Squibb) in combination with gemcitabine/cisplatin(*) have advantages on this attribute over sales-leading gemcitabine/carboplatin.
Pippen, all of Texas Oncology-Baylor at Sammons Cancer Center, an affiliate of US Oncology, co-authored #3122, "Final results of a randomized phase II study demonstrating efficacy and safety of BSI-201, a poly (ADP-Ribose) polymerase (PARP) inhibitor, in combination with gemcitabine/carboplatin (G/C) in metastatic triple negative breast cancer (TNBC).
today announced that US Oncology Research will participate in the BiPar Sciences' Phase III, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C), with or without BSI-201, in patients with Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2-negative metastatic breast cancer.
today announced that US Oncology Research will participate in the BiPar Sciences' Phase III, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C), with or without BSI-201, in patients with Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2-negative metastatic breast cancer.
today announced that US Oncology Research will participate in the BiPar Sciences' Phase III, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C), with or without BSI-201, in patients with Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2-negative metastatic breast cancer.